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Abstract
Purpose Treatment of typical atrial flutter (AFL) with cavo-tricuspid isthmus (CTI) ablation is associated with a high occurrence
rate of new onset atrial fibrillation (AF) during follow-up. There are data to support the addition of pulmonary vein isolation
(PVI) to CTI ablation in patients with both AF and AFL, but the role of cryoballoon PVI only, with no CTI ablation, in AFL
patients with no prior documentation of AF has not been studied.
Methods CRAFT is an international, prospective, randomised, open with blinded assessment, multicentre superiority study comparing
radiofrequency CTI ablation and cryoballoon PVI in patients with typical AFL. Participants with typical AFL are randomised in a 1:1
ratio to either treatment arm, with patients randomised to PVI not receiving CTI ablation. Post-procedural cardiac monitoring is
performed using an implantable loop recorder. The primary endpoint is time to first recurrence of sustained symptomatic atrial
arrhythmia. Key secondary endpoints include (1) total arrhythmia burden at 12 months, (2) time to first episode of AF lasting ≥
2 min, (3) time to recurrence of AFL or ATand (4) procedural and fluoroscopy times. The primary safety endpoint is the composite of
death, stroke/transient ischaemic attack, cardiac tamponade requiring drainage, atrio-oesophageal fistula, requirement for a permanent
pacemaker, serious vascular complications requiring intervention or delaying discharge and persistent phrenic nerve palsy lasting > 24 h.
Conclusion This study compares the outcomes of 2 different approaches to typical AFL—the conventional ‘substrate’-based
strategy of radiofrequency CTI ablation versus a novel ‘trigger’-based strategy of cryoballoon PVI.
Trial registration (ClinicalTrials.gov ID: NCT03401099)
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1 Background
Typical atrial flutter (AFL) is a macro-reentrant tachycardia with
a circuit within the right atrium involving the cavo-tricuspid isth-
mus (CTI) as the critical isthmus. In patients with AFL, the use of
anti-arrhythmic drugs (AADs) to maintain sinus rhythm has lim-
ited success [1]. Radiofrequency ablation (RFA) of the CTI has a
very high acute success rate and is often used as first line treat-
ment. However, as many as half of these patients go on to devel-
op atrial fibrillation (AF) during follow-up [2, 3]. The elevated
risk of AF among patients with AFL indicates the presence of
shared underlying disease processes that remain unchanged with
only CTI ablation. In fact, there is evidence to suggest that pul-
monary vein (PV) ectopy is a common initiating trigger for both
arrhythmias [4, 5].
Previous studies have demonstrated the benefit of a combined
pulmonary vein isolation (PVI) and CTI ablation approach
among patients withAFL [6–8]. A small single centre study even
showed the efficacy of standalone PVI in patients with typical
AFL comparedwithAADs or CTI ablation [1]. Despite this, CTI
ablation has remained the preferred option for patients with typ-
ical AFL, partly because of the perceived complexity of tradi-
tional PVI with RFA, and the high possibility of requiring mul-
tiple procedures to achieve durable PVI [1]. As such, in spite of
the recognition that CTI ablation often represents only a short-
term or partial solution, it continues to be the recommended, first-
line treatment approach for symptomatic, recurrent, typical AFL
[9, 10].
In recent years, cryoballoon ablation has been developed for
AF [11] and has been shown to be non-inferior to RFA in terms
of efficacy and safety profile [12]. Cryoballoon ablation is also
associated with a shorter learning curve, with more reproducible
results across operators and shorter procedure times than RFA,
while ensuring a high probability of creating durable PVI [13].
However, the use of cryoballoon PVI only in patients with typ-
ical AFL and no prior documentation ofAF has not been studied.
2 Methods
2.1 Primary endpoint and hypothesis
The primary hypothesis of the CRAFT study is that cryoballoon
PVI is superior to CTI ablation as first-line treatment for typical
AFL in terms of recurrence of all atrial arrhythmias; it offers the
prospect of more complete arrhythmia elimination with a single
procedure, while resulting in no increase in procedural risk, or in-
catheter laboratory resource utilisation. The primary endpoint is
defined as time to first recurrence of sustained (> 30 s)
symptomatic atrial arrhythmia, including AF, AFL and atrial
tachycardia (AT), following a blanking period of 4 weeks as
assessed by implantable loop recorder (ILR) data.
2.2 Secondary endpoints
Key secondary endpoints include (1) time to first episode of
AF lasting ≥ 2 min, (2) total AF burden at 12 months, (3) time
to recurrence of AFL or AT, (4) procedural and fluoroscopy
times and radiation dose and (5) quality of life (QoL) changes
at 12 months compared with baseline.
2.3 Safety analysis
The primary safety endpoint is the composite of death, stroke/
transient ischaemic attack, cardiac tamponade requiring drain-
age, atrio-oesophageal fistula, requirement for a permanent
pacemaker, serious vascular complications requiring interven-
tion or delaying discharge and persistent phrenic nerve palsy
lasting > 24 h. A list of possible procedure-related adverse
events is shown in Table 1. A definition of terms is provided
in Supplemental Material.
2.4 Study design
CRAFTstudy is an international, prospective, randomized, open
with blinded assessment, multicentre superiority study being
Table 1 Procedure-
related adverse events Air embolism
Atrio-oesophageal perforation or fistula
Atrio-septal defect
Atrioventricular node damage
Bleedings events, including groin
haematoma
Cardiac or coronary artery perforation
Death
Dysphagia
Major vascular complication
Myocardial infarction
Need for unplanned cardiac or vascular
surgery
Pericardial effusion
Pericarditis
Persistent or sustained cardiac arrhythmia
Phrenic nerve paralysis
Pulmonary vein stenosis
Site infection from loop recorder insertion
Stroke or transient ischaemic attack
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performed at 12 sites in the UK and Switzerland. The study is
funded by Medtronic Saarl Ltd., but the investigators are solely
responsible for the study design and conduct, data collection and
analyses, manuscript writing and decision to publish. The study
has been approved by the ethical review committees at each site.
The trial is being conducted in accordance with the principles of
Good Clinical Practice and the Declaration of Helsinki. Block
randomisation is used to allocate participants in a 1:1 ratio to
either:
& ‘Conventional’ treatment with radiofrequency CTI abla-
tion, OR
& ‘Novel’ treatment with cryoballoon PVI
A study flowchart is included for illustration in Fig. 1.
2.5 Participants
The study population consists of patients with persistent AFL in
whom the flutter morphology on standard 12-lead electrocardio-
gram (ECG) is felt to be compatiblewith typical, CTI-dependent-
AFL.Any documentation of previousAF automatically excludes
the patient from the study. Atminimum, patients were required to
have an ambulatory cardiac monitoring or ECGs recorded on at
least 3 different dates to exclude AF. Other key exclusion criteria
include flutter diagnosed solely on ambulatory Holter, suspected
left atrial AFL, prior CTI ablation or PVI, severe left ventricular
systolic dysfunction (left ventricular ejection fraction < 30%) and
morbid obesity (body mass index ≥ 40). A full list of exclusion
criteria is provided in the Supplemental Material. A signed,
informed consent form is obtained from every participant prior
to randomisation.
2.6 Interventions
Ultrasound-guided vascular access and fluoroscopy guidance are
recommended for all cases. For participants presenting to the
catheter laboratory in AFL, entrainment is performed from the
proximal and distal poles of a catheter situated within the coro-
nary sinus, and CTI to confirm the diagnosis of CTI-dependent
AFL. Participants found to have non-CTI-dependent AFL or AF
at the time of the procedurewill be excluded fromundergoing the
allocated intervention they have been randomised to. Instead, the
investigators will be free to offer them ablation treatment appro-
priate to their arrhythmia.
2.6.1 Radiofrequency CTI ablation
In the control arm, the choice of ablation catheter, settings and
overall strategy is at the discretion of individual operators. Using
fluoroscopy only, the aim is to achieve bidirectional conduction
block across the CTI that persists for at least 15min following the
Fig. 1 Study flowchart for CRAFT
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last radiofrequency application, as has previously been de-
scribed [14, 15].
2.6.2 Cryoballoon PVI
A single trans-septal puncture is performed. Routine admin-
istration of heparin is used with a target activated clotting
time of > 250. The Arctic Front Advance cryoballoon
(Medtronic Inc., Minneapolis, USA) and Achieve Advance
Mapping catheter (Medtronic Inc., Minneapolis, USA) are
employed for all cases. The aim is to achieve a single 180-s
‘effective’ freeze for each pulmonary vein. A freeze is con-
sidered ‘effective’ if either of these criteria is met:
& Time to PVI < 60 s if PV signals are discernible on any
pole(s) of the Achieve Advance Mapping catheter, OR
& If PV signals not discernible on any pole(s) of the
Achieve AdvanceMapping catheter, lowering of balloon
temperature below − 40 °C at 60 s
In the event that an effective freeze is not achieved at 60 s,
the freeze is terminated, and further ablation attempts are made
with a better contrast seal. No ‘bonus’ freeze is routinely applied
for any PV once an effective freeze has been delivered. In the
case of 2 unsuccessful attempts to achieve an effective freeze for
any PV, a 240-s freeze is delivered to the vein, followed by an
additional 180-s freeze if PVI is not achieved by the former.
Failure to achieve PVI with this maximum of 4 freezes is not
pursued with further ablation attempts. Targeted treatment of
non-PV triggers or use of focal RF catheter as an adjunct is not
allowed by the protocol.
Prior to removal of the left atrial catheters, an assessment of
each PVis undertakenwith the Achieve AdvanceMapping cath-
eter. If spontaneous PV reconnection is identified, cryoballoon
application is repeated, where required. Participants in persistent
AFL will be cardioverted at the end of the procedure. Protamine
administration is allowed prior to sheath removal.
2.6.3 Implantable loop recorder
The Reveal LINQ (Medtronic Inc., Minneapolis, USA) is im-
planted according to the manufacturer’s instructions during
the ablation procedure. The programmed algorithm for ar-
rhythmia detection is shown in Table 2.
2.7 Follow-up
The study ‘blanking period’ is defined as the initial 4 weeks
following ablation. All AADs are discontinued after this period.
Cross-overs are not permitted in the blanking period, with the
exception of recurrent AFL with 1:1 atrio-ventricular conduction
that is resistant to rate control measures. The use of oral
anticoagulation is mandated for a minimum of 2 months and
subsequently according to individual stroke risk as assessed by
the CHA2DS2-VASc score. Participants are provided with a
symptom diary and asked to transmit monthly ECG recordings
from their loop recorder. In addition, participants are instructed to
record and transmit ECG recordings following arrhythmia-related
symptoms. Transmitted data are reviewed regularly by cardiac
physiologists who are blinded to the randomisation status. The
follow-up duration is 12 months, with planned study visits at 3
and 12 months, when quality of life assessments are performed
with the validated EuroQoL EQ-5D-5L questionnaire. Recurrent
atrial arrhythmias are treated at the discretion of the responsible
clinician. Clinical events will be adjudicated by a panel of cardi-
ologists, who will be blinded to treatment allocation.
2.8 Sample size calculation
In the PReVENT AF study, incidence of AF following
CTI ablation for typical AFL was reported in 52% of
participants at 12 months follow-up using an ILR [7]. In
a meta-analysis by Maskoun et al., the incidence of AF in
a similar patient cohort was 45% over a follow-up period
of 16 months [16]. However, this included studies with
any form of ambulatory ECG monitoring lasting > 7 days.
Based on these data, a 50% incidence of atrial arrhyth-
mias following CTI ablation for typical AFL at 12 months
is assumed. We anticipate that cryoballoon PVI will re-
duce the risk of atrial arrhythmias to 25%. Therefore, with
an alpha value of 0.05 and power of 80%, the number of
participants required to detect a significant difference for
a two-sided test is estimated at 58 per group. To cope with
a potential loss to follow-up of 11%, a minimum of 130
subjects will be enrolled in the study.
Table 2 Algorithm for programming LINQ devices
Parameter Settings
Reason for monitoring Suspected AF
Detection
Tachy On
Interval rate 146 bpm
Duration 12 beats
Brady On
Interval rate 30 bpm
Duration 4 beats
Pauses On
Duration 3 s
AT/AF detection AF only
Sensitivity Less sensitive (nominal)
Ectopy rejection Nominal
AT/AF recording threshold All episodes
AF atrial fibrillation, AT atrial tachycardia, bpm beats per minute
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3 Discussion
The CRAFT study is the first randomised controlled trial that
compares cryoballoon PVI to radiofrequency CTI ablation for
typical AFL. At present, the mode of treatment for symptom-
atic, recurrent, typical AFL by radiofrequency CTI ablation
fails to address the PVs as potential initiating triggers of atrial
arrhythmias [4, 5, 17, 18]. Despite evidence to demonstrate
better clinical outcomes in terms of arrhythmia-free survival
among such patients treated with additional PVI (Table 3),
there has been limited uptake with this approach.
Navarrete et al. found that combined CTI ablation and pul-
monary vein isolation in patients with typical AFL was asso-
ciated with a significant improvement in freedom from atrial
arrhythmias over a follow-up duration of 16months compared
with CTI ablation alone (56% vs 13%) [6]. Similar findings
were reported in PReVENTAF Study I, which was a prospec-
tive, single-blind, randomised controlled trial [7]. However, in
REDUCE AF, the addition of PVI in patients who underwent
CTI ablation for typical AFL only resulted in a significantly
lower rate of AF or atrial tachycardia recurrence among those
aged > 55 years [8].
The Triple A study has previously demonstrated superior-
ity of standalone PVI over CTI ablation in patients with iso-
lated AFL [1]. However, the limitations of this study include
the single-centre study design, small sample size and need for
repeat ablation procedures in more than a third of patients in
the PVI arm to achieve durable PVI, likely because of the use
of RF catheters without contact force measurement capability.
However, with the rapidly expanding field of cryoballoon PVI
which allows more efficient and durable lesion formation in
the PVs, there is a need to evaluate the use of this technology
in typical AFL.
4 Conclusion
The CRAFTstudy is an international, multicentre, randomised
study comparing clinical outcomes with 2 different ap-
proaches to typical AFL—cryoballoon PVI versus radiofre-
quency CTI ablation. It will increase our understanding of the
role of PV triggers in AFL and provide data on whether
cryoballoon PVI could be used as an alternative to radiofre-
quency CTI ablation as a first-line treatment for typical AFL.
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Table 3 Randomised controlled trials on the role of PVI in isolated AFL
Study n Ablation strategy Cardiac monitoring Follow-up period Incidence of atrial
arrhythmias
Navarette [6] 48 CTI vs CTI + PVI 48-h Holter 16 months 56% vs 13%
PReVENTAF [7] 50 CTI vs CTI + PVI ILR 12 months 52% vs 12%
REDUCE AF [8] 216 CTI vs CTI + PVI ILR, event recorder or 7-day Holter 18 months 40% vs 29%
Triple A* [1] 43 CTI vs PVI ILR 17 months 61% vs 10%
AF atrial fibrillation, AFL atrial flutter, CTI cavo-tricuspid isthmus, ILR implantable loop recorder, PVI pulmonary vein isolation
*Subset of whole study cohort
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